Medtronic, a global leader in medical technology, has officially announced the expansion of its CE Mark for the Affera Mapping and Ablation System, specifically the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and mapping catheter. This regulatory milestone allows the device to be used in the treatment of ventricular tachycardia (VT) and premature ventricular complexes (PVCs), marking a significant shift in the therapeutic landscape for complex cardiac arrhythmias. By integrating high-density mapping with a dual-energy ablation platform, Medtronic aims to address long-standing limitations in the treatment of life-threatening heart rhythm disorders that originate in the heart’s lower chambers.
The expansion comes at a time when the electrophysiology (EP) market is undergoing a rapid transition toward pulsed field ablation, a non-thermal energy source that targets cardiac tissue with high-precision electrical pulses. While much of the initial industry focus has been on atrial fibrillation (AFib), Medtronic’s move into the ventricular space signals a strategic effort to capture a growing segment of the market where traditional treatment modalities have historically fallen short.
The Pathophysiology of Ventricular Tachycardia and Clinical Need
Ventricular tachycardia is a cardiac rhythm disorder characterized by a fast, abnormal heart rate that starts in the ventricles, the heart’s lower pumping chambers. Because the ventricles are responsible for pumping oxygenated blood to the rest of the body, a sustained episode of VT can prevent the heart from filling properly, leading to a dangerous drop in blood pressure and, in many cases, sudden cardiac arrest.
Currently, the standard of care for patients at risk of VT involves a combination of pharmacological interventions, such as anti-arrhythmic drugs, and the implantation of an implantable cardioverter-defibrillator (ICD). While ICDs are effective at terminating lethal arrhythmias through pacing or high-energy shocks, they do not prevent the occurrence of the arrhythmia itself. Furthermore, repeated shocks from an ICD can be painful for patients and are associated with decreased quality of life and increased mortality.
Catheter ablation has emerged as a vital tool for reducing the "burden" of VT by destroying the specific areas of myocardial tissue responsible for triggering the irregular signals. However, Medtronic and many clinical experts have characterized previous ablation approaches as "suboptimal." The ventricles are significantly thicker than the atria, making it difficult for traditional thermal energy sources like radiofrequency to create deep enough lesions to reach the source of the arrhythmia without risking damage to adjacent structures or causing complications like steam pops or esophageal injury.
Technical Innovation: The Sphere-9 and Affera System
The Sphere-9 catheter is the centerpiece of the Affera Mapping and Ablation System, which Medtronic acquired through its $925 million purchase of Affera, Inc. in August 2022. The technology is unique in the EP space due to its "all-in-one" design and dual-energy capabilities.
Integrated Mapping and Ablation
Unlike traditional workflows that may require switching between different catheters for mapping the heart’s electrical activity and performing the actual ablation, the Sphere-9 features a 9mm lattice-tip electrode. This allows electrophysiologists to create high-density maps of the ventricular anatomy and electrical circuits and then immediately deliver therapy using the same device. This integration is designed to reduce procedure times, minimize the need for multiple catheter exchanges, and improve the accuracy of lesion placement.
Dual-Energy Versatility
The Sphere-9 is capable of delivering both Radiofrequency (RF) and Pulsed Field Ablation (PFA) energy. RF ablation uses thermal energy to create lesions, which remains a gold standard for certain types of tissue contact and depth. PFA, conversely, utilizes high-voltage electrical fields to create pores in cell membranes—a process known as irreversible electroporation. Because PFA is non-thermal and tissue-selective, it carries a lower risk of damaging non-cardiac structures such as the phrenic nerve or the coronary arteries, which are often in close proximity to the ventricular walls.
The ability to toggle between these two energy sources allows physicians to tailor the treatment to the specific anatomy and pathology of the patient, providing a level of procedural flexibility that was previously unavailable in a single device.
Chronology of Development and Regulatory Milestones
The journey of the Affera system from a startup innovation to a cornerstone of Medtronic’s EP portfolio has been marked by several key milestones:
- August 2022: Medtronic completes the acquisition of Affera, Inc., signaling its intent to compete aggressively in the nascent PFA market.
- March 2023: The Affera Mapping and Ablation System receives its initial CE Mark for the treatment of atrial fibrillation, specifically targeting pulmonary vein isolation (PVI) and linear lesions.
- May 2024: Medtronic reports robust growth in its PFA segment during its fiscal fourth-quarter earnings, citing rapid physician adoption in Europe.
- September 2024: The CE Mark is expanded to include ventricular tachycardia and premature ventricular complexes, opening the door for the technology to be used in high-complexity cases across the European Union and other countries recognizing the CE Mark.
In the United States, the Sphere-9 catheter remains an investigational device. Medtronic has completed enrollment in the SPHERE Per-AF pivotal trial, which is evaluating the safety and efficacy of the system for the treatment of persistent atrial fibrillation. The data from this trial will be critical for securing FDA pre-market approval (PMA) in the coming years.
Competitive Landscape and Market Dynamics
The electrophysiology market is currently valued at approximately $8 billion and is growing at a double-digit rate, driven largely by the "PFA revolution." Medtronic is locked in a fierce battle for market share with other medical device giants, including Boston Scientific, Johnson & Johnson (Biosense Webster), and Abbott Laboratories.
Boston Scientific was the first to gain FDA approval for a PFA system with its Farapulse technology, which has seen explosive growth due to its ease of use and safety profile. Johnson & Johnson is also advancing its Varipulse platform, while Abbott recently entered the fray with its Volt PFA system.
However, Medtronic’s expansion into the ventricular space provides a competitive edge. Most current PFA systems are optimized for the atria. By securing an indication for VT and PVCs, Medtronic is positioning the Sphere-9 as a more versatile tool capable of handling the most difficult cases in the EP lab.
The market is also seeing interest from specialized startups. Field Medical, led by Steven Mickelsen—the original founder of Farapulse—is specifically developing a PFA system designed for the challenges of ventricular ablation. Medtronic’s regulatory head start in Europe for this indication places it in a strong position to establish clinical leadership before these emerging competitors reach the commercial stage.
Strategic Implications and Executive Response
The expansion of the Sphere-9’s indications is a central component of Medtronic’s broader strategy to revitalize its Cardiovascular portfolio. Rebecca Seidel, President of Electrophysiology Therapies at Medtronic, emphasized the strategic importance of this development.
"Indication expansion to include ventricular arrhythmias unlocks another fast-growing market opportunity to keep building on our momentum," Seidel stated. She noted that the unmet need in the VT space is significant, and the ability to provide a safer, more efficient tool for these complex procedures is a win for both clinicians and patients.
Industry analysts suggest that the integration of mapping and ablation into a single catheter not only improves clinical outcomes but also offers economic benefits to hospitals. By reducing the number of disposables required for a single procedure and potentially shortening lab occupancy time, the Affera system aligns with the global trend toward value-based healthcare.
Clinical Outlook and Broader Impact
The introduction of PFA into the ventricles is expected to encourage earlier intervention for patients with VT and PVCs. Historically, many physicians have been hesitant to recommend ablation for ventricular arrhythmias unless the patient was in a "VT storm" or had failed multiple medications, due to the inherent risks of thermal ablation in the thick ventricular muscle.
The safety profile of pulsed field ablation could change this paradigm. If physicians can create deep, transmural lesions without the risk of collateral damage, ablation may become a first-line or second-line therapy rather than a last resort. For patients with PVCs—which, while often benign, can lead to PVC-induced cardiomyopathy (a weakening of the heart muscle) if left untreated—the availability of a more precise ablation tool could prevent long-term heart failure.
As Medtronic begins the commercial rollout of the expanded Sphere-9 indications in Europe, the global EP community will be watching closely. The real-world data generated from these ventricular cases will likely influence regulatory decisions in other geographies, including the United States and Asia, and could set a new standard for how the world’s most dangerous heart rhythms are managed.
With this CE Mark expansion, Medtronic has not only broadened its product utility but has also reinforced its commitment to solving the most difficult challenges in cardiac care through technological convergence. The success of the Sphere-9 in the ventricles may well determine the next leader in the high-stakes race for dominance in the electrophysiology market.
